Cases & Deals

  • Home
  • Practices
  • Celularity acquires certain assets from TNK Therapeutics

Share

Celularity acquires certain assets from TNK Therapeutics

August 2017

Clients Celularity Inc.

Jones Day advised Celularity Inc. in connection with its acquisition from TNK Therapeutics of certain intellectual property rights related to TNK's proprietary chimeric antigen receptor ("CAR") constructs and related CARs.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.